Texas is currently home to 4852 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: Children's Medical Center Dallas, UT Southwestern, Dallas, Texas
Conditions: Langerhans Cell Histiocytosis
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: University of Texas MD Anderson, Houston, Texas
Conditions: Merkel Cell Carcinoma
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Recruiting
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
Artificial Intelligence (AI) Cytopathology Trial
Recruiting
Purpose The primary objective of the study is to compare interpretation of EUS FNA/FNB samples for adequacy between ROSE and AI at bedside. To compare accuracy of preliminary diagnosis results between ROSE and AI at bedside versus final pathology report. Research design This is a prospective single center study to compare performance characteristics in the interpretation of EUS FNA/FNB samples between AI and ROSE. Procedures to be used Eligible patients will undergo EUS guided FNA/FNA of PSLs... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/15/2023
Locations: Memorial Hermann Hospital, Houston, Texas
Conditions: Pancreatic Solid Lesions
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
Recruiting
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: Baylor Scott and White Research Institute, Dallas, Texas
Conditions: Non Small Cell Lung Cancer, Healthy
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Cancer
Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up
Recruiting
Proton therapy is a limited medical resource that is more expensive than conventional x-ray therapy. To correctly measure the success of proton therapy in treating different conditions, it is important to check a patient's health status after their treatment is finished. Checking on the progress of patients over many years (called long-term follow-up) is needed because the long-term effects of proton therapy are not well known.
Gender:
ALL
Ages:
All
Trial Updated:
02/06/2023
Locations: Texas Center for Proton Therapy, Irving, Texas
Conditions: Cancer
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
Recruiting
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE). We hypothesize that atezolizumab and bevacizumab can appropriately bridge patients with HCC beyond MC to transplantation and not increase the risk of 1-year post-transplant rejection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2023
Locations: Houston Methodist Research Institute, Houston, Texas
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer
Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease
Recruiting
Inflammation occurs in many brain diseases including Alzheimer's disease. In Alzheimer's disease, amyloid starts accumulating decades before the start of forgetfulness. Basic scientists have reported that inflammation but not amyloid is linked to forgetfulness. When people pinch a finger, it gets swollen. Similar changes occur in brain from various causes. New medications are under development to help healing and prevent permanent damages in the brain. When people pinch a finger, they can check... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/20/2023
Locations: Houston Methodist Research Institute, Houston, Texas
Conditions: Alzheimer Disease, Healthy
Rett Syndrome Registry
Recruiting
The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett s... Read More
Gender:
ALL
Ages:
Between 0 years and 99 years
Trial Updated:
01/09/2023
Locations: Children's Health, Dallas, Texas
Conditions: Rett Syndrome, Rett Syndrome, Atypical, Genetic Disease, Genetic Diseases, X-Linked, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Neurologic Disorder, Neurodevelopmental Disorders, Nervous System Diseases
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
Recruiting
In previous studies, Proton Beam Radiation Therapy (PBRT) has been found to show better results in treating patients with cancer, both because there is better control of where in the body the radiation is directed and because it is associated with less severe long term side effects. However, there is limited published data demonstrating these results. The goal of the Proton and Photon Consortium Registry (PPCR) is to enroll children treated with radiation in order to describe the population that... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
01/05/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Pediatric Patients Treated With Radiation Therapy
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Recruiting
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2023
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation, Small Cell Lung Cancer, SCLC